Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Covington
US Army
Boehringer Ingelheim
Medtronic
Julphar
Mallinckrodt

Generated: September 23, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DROSPIRENONE

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Clinical Trials for Drospirenone

Trial ID Title Status Sponsor Phase Summary
NCT00102141 Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women Completed Bayer Phase 3 The objective of the study is to evaluate the effects of Angeliq on BP over a period of 8 weeks in postmenopausal women who may benefit from hormone replacement therapy (HRT) for the relief of vasomotor symptoms and who have hypertension.
NCT00185419 A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception Completed Bayer Phase 3 The purpose of this study is to evaluate the effectiveness in terms of prevention of pregnancy and safety of the oral contraceptive Yasmin and Marvelon on cycle control in healthy Chinese women
NCT00185484 Efficacy and Safety Oral Contraceptive Study Completed Bayer Phase 3 The purpose of this study is to determine whether the study drug is effective in prevention of pregnancy in healthy women in reproductive age
NCT00266032 Study on Safety and Efficacy of an Oral Contraceptive in Long Cycles Completed Bayer Phase 3 The purpose of the study is to determine safety and efficacy of long-cycle regimens of an oral contraceptive.
NCT00302848 European Active Surveillance Study (EURAS) Completed Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma Phase 4 EURAS is a multi-national, controlled, prospective, post-marketing, non-intervention cohort study of new users of drospirenone/ethinylestradiol (DRSP/EE), levonorgestrel/ethinylestradiol (LNG/EE) and other oral contraceptives (OCs) under routine conditions of medical practice in seven European countries. Baseline survey and semiannual, active follow-up are based on postal questionnaires, with validation of reported events by the women's treating physicians. A multifaceted 4-level follow-up procedure will be established to ensure low loss to follow-up rates. The objective of the study is the investigation of the incidence of rare serious adverse events associated with the use of new and established OCs, and specifically the incidence of thromboembolic events.
NCT00302848 European Active Surveillance Study (EURAS) Completed Center for Epidemiology and Health Research, Germany Phase 4 EURAS is a multi-national, controlled, prospective, post-marketing, non-intervention cohort study of new users of drospirenone/ethinylestradiol (DRSP/EE), levonorgestrel/ethinylestradiol (LNG/EE) and other oral contraceptives (OCs) under routine conditions of medical practice in seven European countries. Baseline survey and semiannual, active follow-up are based on postal questionnaires, with validation of reported events by the women's treating physicians. A multifaceted 4-level follow-up procedure will be established to ensure low loss to follow-up rates. The objective of the study is the investigation of the incidence of rare serious adverse events associated with the use of new and established OCs, and specifically the incidence of thromboembolic events.
NCT00356447 Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms. Completed Bayer Phase 3 The study evaluates in Chinese post-menopausal women the combination of drospirenone 2 mg and estradiol 1 mg for the treatment of climacteric symptoms, such as hot flushes (vasomotor symptoms) and uro-genital complaints.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Drospirenone

Condition Name

Condition Name for Drospirenone
Intervention Trials
Contraception 29
Polycystic Ovary Syndrome 10
Healthy 9
Dysmenorrhea 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Drospirenone
Intervention Trials
Syndrome 12
Polycystic Ovary Syndrome 12
Dysmenorrhea 7
Premenstrual Syndrome 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Drospirenone

Trials by Country

Trials by Country for Drospirenone
Location Trials
United States 162
Germany 48
China 48
Japan 29
United Kingdom 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Drospirenone
Location Trials
Pennsylvania 10
California 9
Florida 8
Arizona 7
Washington 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Drospirenone

Clinical Trial Phase

Clinical Trial Phase for Drospirenone
Clinical Trial Phase Trials
Phase 4 18
Phase 3 38
Phase 2/Phase 3 2
[disabled in preview] 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Drospirenone
Clinical Trial Phase Trials
Completed 57
Recruiting 13
Unknown status 6
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Drospirenone

Sponsor Name

Sponsor Name for Drospirenone
Sponsor Trials
Bayer 38
Estetra 8
Merck Sharp & Dohme Corp. 3
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Drospirenone
Sponsor Trials
Industry 68
Other 35
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Fish and Richardson
Colorcon
Chinese Patent Office
Accenture
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.